secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2026-05-12T11:20:21+00:00
Accession:  0001193125-26-218175
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q1 cash $29.3M; closed $180M upfront financing; expects CRL by June 20, 2026; new CEO appointed
--------------------------------------------------------------------------------

- Q1 cash, equivalents, and marketable securities $29.3M; net loss $10.2M, operating expenses $10.5M.
- Closed private placement of up to $354M ($180M upfront + $174M milestone warrants).
- Andrew D. Goldberg, MD appointed CEO and board member; Christopher Martin added as director.
- Expects CRL from FDA by June 20, 2026; to resubmit NDA in Q4 2026 with new manufacturer Adare.
- Jaime Xinos departs as CCO May 31; Lucian Iancovici becomes Chair; Tom King steps down June 8.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/0001193125-26-218175-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000119312526218175/d854692d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218175

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer